Assistant Director Flow and Image Cytometry Roswell Park Cancer Institute

目前的申请寻求Hans Minderman博士的工资支持，Hans Minderman博士担任 罗斯韦尔的流动和图像细胞学共享资源(FICSR)助理主任 帕克癌症研究所。该职位设立于2007年，负责监督 中提供的各种成像(共聚焦、活细胞成像)和流式细胞仪平台 设施，为当时的新ImageStream技术建立和实施一个计划，并 将他在这些领域的丰富经验应用于与 FICSR调查员用户群。拥有超过30年的FLOW临床应用经验 和图像细胞术(在罗斯威尔公园癌症研究所工作25年)，明德曼博士 Career与研究所的许多研究人员在NIH资助的项目上进行了合作。这个 肿瘤免疫学和免疫疗法(TII)癌症中心支持赠款(CCSG)计划，共同- 由Odunsi博士领导，他是此应用程序的单位主任，是 FICSR；和NIH资助的众多研究人员积极合作， 咨询Minderman博士，与PAR16-025资助的目的相称 机会。具体地说，在DR下开发的ImageStream细胞仪应用程序 Minderman的方向在许多研究人员的研究努力中发挥着重要作用 奥敦西博士领导的TII和卵巢孢子项目。在持续不断的努力中，提供TII和 2015年12月，孢子计划成员使用尖端细胞仪技术，RPCI 购买了一台Helios细胞仪，使小细胞的高维多重表型成为可能 样本大小，如肿瘤微环境的活组织检查。明德曼医生将应用他的 在建立和实施非常成功的ImageStream计划方面的专业知识 咨询并积极与奥敦西博士的研究小组合作，以实施 Helios技术以及开发和验证其应用程序。

The current application seeks salary support for Hans Minderman, PhD who serves as the Assistant Director of the Flow and Image Cytometry Shared Resource (FICSR) of the Roswell Park Cancer Institute. This position was created in 2007 to oversee the research applications of the various imaging (confocal, live cell imaging) and flow cytometry platforms available in the facility, to establish and implement a program for the then novel ImageStream technology and to apply his extensive experience in these areas in collaborations and consultations with the FICSR investigator user base. With over 30 years of experience in clinical applications of flow and image cytometry (25 years at Roswell Park Cancer Institute), Dr Minderman throughout his career has collaborated with many investigators at the Institute on NIH funded projects. The tumor immunology & immunotherapy (TII) Cancer Center Support Grant (CCSG) program, co- led by Dr Odunsi, who serves as the unit director on this application, is the major user base of the FICSR; and numerous NIH-funded researchers in this program actively collaborate and consult with Dr Minderman commensurate with the purpose of the PAR16-025 funding opportunity. Specifically, the ImageStream cytometry applications developed under Dr Minderman’s direction play an important role in the research efforts of many researchers in the TII and ovarian SPORE programs led by Dr Odunsi. In the ongoing effort to provide the TII and SPORE program members with cutting edge cytometry technology, RPCI in December 2015 purchased a Helios cytometer which enables high dimensional multiplex phenotyping of small sample sizes such as biopsies of the tumor microenvironment. Dr Minderman will apply his expertise in setting up and implementing the highly successful ImageStream program to consulting and actively collaborating with Dr Odunsi’s research group to implementing the Helios technology and developing and validating its applications.